Antonios Drakopoulos is a medicinal chemist and chemical biologist with extensive experience in computational and experimental drug discovery. He combines expertise in organic synthesis, chemical biology, and computer-aided drug design to advance small-molecule therapeutics. Antonios has worked in industrial R&D at AstraZeneca and NovaMechanics Ltd., contributing to projects across the Early CVRM portfolio, including small molecules and PROTACs, integrating molecular modeling, docking, free energy calculations, and machine learning-driven approaches. His academic experience spans PhD research on opioid receptor oligomerization at the University of Würzburg, postdoctoral work on covalent probes in kinase chemical biology at the University of Gothenburg, and international research stays at University of Minho and University of Birmingham. He has been awarded prestigious fellowships and honors, including a Marie Skłodowska-Curie EUTOPIA-SIF fellowship, participation in the 71st Lindau Nobel Laureate Meeting, and first prize in the Merck Compound Challenge (2022) as part of Team UGOT. His research output includes publications in leading journals such as J. Med. Chem. - ACS and Angew. Chem. - Wiley, along with invited contributions to the EuroMedChem Talents Collection (ChemMedChem). Antonios has supervised MSc students, taught undergraduate chemistry courses, and collaborates across multidisciplinary teams, bridging computational and experimental disciplines in drug discovery.
Antonios Drakopoulos is a medicinal chemist and chemical biologist with extensive experience in computational and experimental drug discovery. He combines expertise in organic synthesis, chemical biology, and computer-aided drug design to advance small-molecule therapeutics. Antonios has worked in industrial R&D at AstraZeneca and NovaMechanics Ltd., contributing to projects across the Early CVRM portfolio, including small molecules and PROTACs, integrating molecular modeling, docking, free energy calculations, and machine learning-driven approaches. His academic experience spans PhD research on opioid receptor oligomerization at the University of Würzburg, postdoctoral work on covalent probes in kinase chemical biology at the University of Gothenburg, and international research stays at University of Minho and University of Birmingham. He has been awarded prestigious fellowships and honors, including a Marie Skłodowska-Curie EUTOPIA-SIF fellowship, participation in the 71st Lindau Nobel Laureate Meeting, and first prize in the Merck Compound Challenge (2022) as part of Team UGOT. His research output includes publications in leading journals such as J. Med. Chem. - ACS and Angew. Chem. - Wiley, along with invited contributions to the EuroMedChem Talents Collection (ChemMedChem). Antonios has supervised MSc students, taught undergraduate chemistry courses, and collaborates across multidisciplinary teams, bridging computational and experimental disciplines in drug discovery.